What is Cofactor Genomics?
Cofactor Genomics is a pioneering biotechnology firm specializing in the development of advanced RNA-Seq technology. The company is primarily recognized for its OncoPrism assay, a sophisticated diagnostic tool designed to predict patient responses to immunotherapy by analyzing multidimensional biomarkers. By bridging the gap between complex genomic data and actionable clinical insights, Cofactor Genomics empowers healthcare providers to tailor cancer treatments to individual patient profiles. Currently integrated into clinical trials across more than 24 healthcare systems, the company serves a critical role in the evolution of immune-oncology, providing pathologists and oncologists with the precision tools necessary to improve patient outcomes in highly complex disease environments.
How much funding has Cofactor Genomics raised?
Cofactor Genomics has raised a total of $21.5M across 5 funding rounds:
Other Financing Round
$2.6M
Other Financing Round
$120K
Series A
$18M
Debt
$350K
Debt
$424K
Other Financing Round (2015): $2.6M with participation from BioGenerator, 7percent Ventures, Jude Gomila, Paul Buchheit, David Lee, AME Cloud, TenOneTen, and Data Collective
Other Financing Round (2015): $120K led by Y Combinator
Series A (2017): $18M supported by Wilson Sonsini Goodrich & Rosati, Data Collective, Menlo Ventures, Ascension Ventures, Y Combinator, iSelect Fund Management, and Stanford
Debt (2020): $350K featuring PPP
Debt (2021): $424K backed by PPP
Key Investors in Cofactor Genomics
Ascension Ventures
A strategic healthcare venture firm that invests on behalf of leading community health systems to support private companies transforming the healthcare industry.
Data Collective
A venture capital firm focused on supporting technology-driven companies that leverage data to solve complex, real-world problems.
Y Combinator
A prominent startup accelerator and seed-stage investor that provides capital and mentorship to high-growth technology businesses.
What's next for Cofactor Genomics?
With a robust foundation established through successive rounds of financing, Cofactor Genomics is well-positioned to accelerate the commercial adoption of its diagnostic platforms. The strategic focus moving forward involves expanding the reach of the OncoPrism assay within the broader healthcare ecosystem, leveraging existing partnerships with major health systems to standardize precision medicine protocols. As the company transitions from clinical validation to widespread market integration, the focus will likely shift toward enhancing its data-driven biomarker discovery engine and exploring new therapeutic indications. This trajectory suggests a long-term commitment to transforming oncology care through high-fidelity genomic analysis and scalable diagnostic infrastructure.
See full Cofactor Genomics company page
